| __timestamp | BioCryst Pharmaceuticals, Inc. | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 2917513 |
| Thursday, January 1, 2015 | 13047000 | 7878291 |
| Friday, January 1, 2016 | 11253000 | 8366794 |
| Sunday, January 1, 2017 | 13933000 | 6610381 |
| Monday, January 1, 2018 | 29514000 | 6556000 |
| Tuesday, January 1, 2019 | 37121000 | 6930000 |
| Wednesday, January 1, 2020 | 67929000 | 8758000 |
| Friday, January 1, 2021 | 118818000 | 10806000 |
| Saturday, January 1, 2022 | 159371000 | 9844000 |
| Sunday, January 1, 2023 | 213894000 | 13481000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Soleno Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc. over the past decade.
From 2014 to 2023, BioCryst Pharmaceuticals has seen a staggering increase in SG&A expenses, growing by over 2,700%, from approximately $7.5 million to $214 million. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Soleno Therapeutics has maintained a more conservative growth, with expenses increasing by about 360%, from $2.9 million to $13.5 million.
This disparity highlights differing strategic approaches: BioCryst's expansive growth versus Soleno's steady, controlled scaling. Investors and stakeholders should consider these trends when evaluating potential opportunities in the pharmaceutical sector.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Summit Therapeutics Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Jazz Pharmaceuticals plc and Soleno Therapeutics, Inc.
CRISPR Therapeutics AG or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
Merus N.V. vs Soleno Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.